BIOMAT Database Logo BIOMAT Database Logo

[Treatment of patients with acute coronary insufficiency with thrombolytic preparations (fibrinolysin and thrombolytin)]. 1968

E Sh Khalfen, and N P Orlova

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014357 Trypsin A serine endopeptidase that is formed from TRYPSINOGEN in the pancreas. It is converted into its active form by ENTEROPEPTIDASE in the small intestine. It catalyzes hydrolysis of the carboxyl group of either arginine or lysine. EC 3.4.21.4. Tripcellim,Trypure,beta-Trypsin,beta Trypsin

Related Publications

E Sh Khalfen, and N P Orlova
[The use of fibrinolysin in patients with acute coronary insufficiency and thromboembolic complications].
December 1966, Terapevticheskii arkhiv,
E Sh Khalfen, and N P Orlova
[The use of fibrinolysin in patients with acute coronary insufficiency and thromboembolic complications].
December 1966, Terapevticheskii arkhiv,
E Sh Khalfen, and N P Orlova
[Treatment of acute thrombophlebitis with thrombolytin electrophoresis].
June 1972, Vestnik khirurgii imeni I. I. Grekova,
E Sh Khalfen, and N P Orlova
[The effect of fibrinolysin with heparin and thrombolytin on blood coagulation indices in myocardial infarct patients with thromboembolic complications].
August 1971, Terapevticheskii arkhiv,
E Sh Khalfen, and N P Orlova
[Therapy of coronary insufficiency with theophyllin preparations].
September 1953, Medizinische Monatsschrift,
E Sh Khalfen, and N P Orlova
[Thrombolytic preparations and anticoagulants in the treatment of patients with thrombotic stroke].
August 1974, Vrachebnoe delo,
E Sh Khalfen, and N P Orlova
Early thrombolytic treatment in acute coronary thrombosis.
December 1993, Australian and New Zealand journal of medicine,
E Sh Khalfen, and N P Orlova
[The treatment of acute arterial thrombosis and embolism of the extremities with thrombolytic preparations].
June 1969, Khirurgiia,
E Sh Khalfen, and N P Orlova
[Treatment of acute and chronic coronary insufficiency with carbochromen].
March 1970, Arzneimittel-Forschung,
E Sh Khalfen, and N P Orlova
Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes.
November 2000, The Journal of the American Osteopathic Association,
Copied contents to your clipboard!